Assembly Biosciences ASMB
NASDAQ ASMB
$36.48 +0.35 (+0.97%)
As of: Sep 4, 2026 · 3:15 PM EDT

Assembly Biosciences (ASMB) Current Deferred Tax Assets (2017)

Assembly Biosciences (ASMB) posted quarterly Current Deferred Tax Assets of $4.9 million for Q4 2017.

Analysis

Assembly Biosciences (ASMB) Current Deferred Tax Assets (2017) Analysis & Trends

Assembly Biosciences' Current Deferred Tax Assets history runs 1 years deep, the most recent figure standing at $4.9 million for Q4 2017.

  • In Q4 2017, Current Deferred Tax Assets changed N/A year-over-year to $4.9 million; the TTM figure through Dec 2017 stood at $4.9 million (changed N/A YoY), while the FY2017 annual figure was $4.9 million, changed N/A from the prior year.
  • Current Deferred Tax Assets for Q4 2017 stood at $4.9 million.
  • The five-year high for Current Deferred Tax Assets was $4.9 million in Q4 2017, with the low at $4.9 million in Q4 2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.51 Bn 130.66 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.24 Bn 77.25 Bn 3.93 Bn
3 Argenx Se 63.46 Bn 58.28 Bn 1.37 Bn
4 Moderna 57.89 Bn 52.75 Bn 52.00 Mn
5 Revolution Medicines 44.02 Bn 44.02 Bn -
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.49 Bn 32.19 Bn 992.69 Mn
8 Royalty Pharma 28.43 Bn 27.59 Bn -
9 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
10 Assembly Biosciences 689.20 Mn 368.83 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 4.90 Mn